Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
product photo
product photo

SETTING A STANDARD IN ILIAC TREATMENT

Omnilink Elite is a next generation Cobalt Chromium stent proven in challenging iliac cases.1 The Cobalt Chromium and Multi-Link design create a strong yet highly flexible stent that conforms to tortuous anatomies.

 

 

1 Adapted from “Modern Endovascular Management of Patients with Iliac Artery Disease. Results from the MOBILITY Trial”, M Jaff, SCAI 2012

FEATURES
ORDERING INFO

ELITE ENGINEERING, PERFORMANCE AND RESULTS

ELITE ENGINEERING

State of the Art Stent Design

  • Thin struts designed to minimize vessel wall injury1
  • No shortening2 for superb accuracy
  • Strong yet flexible to conform to the natural anatomy of iliac arteries
ELITE PERFORMANCE

High Performance Catheter

  • Dual-layer, low profile balloon designed to treat difficult to reach lesions and heavily calcified plaques
  • Pushable catheter designed to easily navigate tortuous anatomies
ELITE RESULTS

Proven in Complex Patients

  • No exclusions for calcified lesions, occlusions and multi-level PAD3
  • 95% freedom from Clinically-Driven TLR at 9 months3
  • Patients walked further, faster and climbed more
    stairs at 9 months3*

 

1. The ISAR-STEREO and ISAR-STEREO-2 trials studied stents designed with Multi-Link technology.
Kastrati, et al. Intracoronary stenting and angiographic results strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103:2816-2821.
Pache, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. JACC 2003; 41:1283-8.
Kolandaivelu et al. Stent thrombogenecity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer- drug coating. Circulation 2011; 1400-1408.
2. -1.81% shortening for 8.0 x 39 mm size. Tests performed by and data on file at Abbott Vascular.
3. Adapted from “Modern Endovascular Management of Patients with Iliac Artery Disease. Results from the MOBILITY Trial”, M Jaff, SCAI 2012
* WIQ was used to assess walking distance, walking speed and stair climbing for study subjects.

omnilink-elite-ordering-info

AP2946450-WBO Rev. A

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO